Cell Source, Inc. (CLCS)

OTCMKTS: CLCS · Delayed Price · USD
0.700
0.000 (0.03%)
May 25, 2022 4:00 PM - Market closed
Market Cap24.11M
Revenue (ttm)n/a
Net Income (ttm)-5.47B
Shares Out34.44M
EPS (ttm)-0.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,000
Open0.700
Previous Close0.700
Day's Range0.700 - 0.700
52-Week Range0.370 - 2.250
Beta0.37
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CLCS

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other ...

IndustryBiotechnology
Founded2011
Employees1
Stock ExchangeOTCMKTS
Ticker SymbolCLCS
Full Company Profile

News

There is no news available yet.